Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of an Exclusive Patent License: Allogeneic Therapy for the Treatment of Autoimmune Disease Using Chimeric Antigen Receptors Targeting CD19 Only written comments and/or complete applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before March 5, 2021 will be considered.
View Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before February 9, 2021 will be considered.
View Prospective Grant of an Exclusive Patent License: Development and Commercialization of Certain Fusion Proteins and Their Use for the Treatment of Humans With Short Stature Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before February 9, 2021 will be considered.
View Prospective Grant of an Exclusive Patent License: Development and Commercialization of CD33-Specific Chimeric Antigen Receptor (CAR) Therapies for CD33-Expressing Malignancies Using Natural Killer Cells (NK Cells) Transduced With Retroviral or Lentiviral Vectors Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before January 29, 2021 will be considered.
View Prospective Grant of an Exclusive Patent License: Use of A CD47 Phosphorodiamidate Morpholino Oligomer for the Treatment, Prevention, and Diagnosis Of Cancer Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before January 12, 2021 will be considered.
View Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like Tyrosine Kinase 3 (FLT3) Expressing Malignancies Using Natural Killer Cells (NK Cells) Transduced With Retroviral or Lentiviral Vectors Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before January 12, 2021 will be considered.
View Prospective Grant of Exclusive Patent License: Treatment and Prevention of Neuropathic Pain With P2Y14 Antagonists Only written comments and/or applications for a license which are received by the NIDDK Technology Advancement Office December 3, 2020 will be considered.
View Prospective Grant of an Exclusive Patent License: Field-Deployable Mass Spectrometer Diagnostic for SARS, SARS-CoV-2 and Other Viruses, Bacteria and Bacterial Serovar, and Drug Impurities Only written comments and/or applications for a license which are received by the Food and Drug Administration's Technology Transfer Program on or before November 30, 2020 will be considered.
View Prospective Grant of Exclusive Patent License: Treatment of Hermansky-Pudlak Syndrome and Idiopathic Pulmonary Fibrosis Only written comments and/or applications for a license which are received by the National Human Genome Research Institute's Technology Transfer Office on or before November 23, 2020 will be considered.
View Prospective Grant of an Exclusive Patent License: Development of a Direct Ocular Administered Formulation of Metformin for Use in Therapeutic Treatment of Retinal Degenerative Diseases in Humans Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before November 6, 2020 will be considered.
View Prospective Grant of an Exclusive Patent License: Development of a Topical Ointment Containing Immunostimulatory CpG Oligodeoxynucleotides (ODN) for Dermatological Wound Healing Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before November 6, 2020 will be considered.
View Prospective Grant of an Exclusive Patent License: Allogeneic Therapy Using an Armored Payload and Chimeric Antigen Receptors Targeting GPC3 Only written comments and/or complete applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before October 16, 2020 will be considered.
View Prospective Grant of an Exclusive Patent Commercialization License: Method of Treating Periodontal Disease via ENPP1 Inhibition Only written comments and/or applications for a license which are received by the National Heart, Lung, and Blood Institute Office of Technology Transfer and Development on or before October 9, 2020 will be considered.
View Prospective Grant of an Exclusive Patent License: Anti-CD56 as an Antibody-Drug Conjugate (“ADC”) or Non-ADC To Target Glioblastoma Either Alone or in Combination With Other Potential Immuno-Oncology Drugs. Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before September 14, 2020 will be considered.
View Prospective Grant of an Exclusive Start-Up Patent License for Evaluation: Immunotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma Only written comments and/or applications for a license which are received by the National Heart, Lung, and Blood Institute on or before August 28, 2020 will be considered.
View Prospective Grant of an Exclusive Patent License: Development and Commercialization of Therapies To Treat IGF-1 Deficiency and Achondroplasia Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before August 20, 2020 will be considered.
View Prospective Grant of an Exclusive Patent License: Allogeneic Therapy Using Chimeric Antigen Receptors Targeting GPC3 Only written comments and/or complete applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before August 14, 2020 will be considered.
View Prospective Grant of an Exclusive Patent License: Gene Therapy for Ocular Disease Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center (representing the National Eye Institute and the National Heart, Lung, and Blood Institute (representing the National Institute on Deafness and Other Communication Disorders) on or before July 31, 2020 will be considered.
View Prospective Grant of an Exclusive Patent License: Gene Therapy for Treatment or Prevention of Niemann-Pick Disease Type C1, Subject to Existing Three Non-Exclusive Licenses Only written comments and/or applications for a license which are received by the National Human Genome Research Institute's Technology Transfer Office on or before July 31, 2020 will be considered.
View Prospective Grant of Exclusive Patent Commercialization License: N6, a Novel, Broad, Highly Potent HIV-Specific Antibody and a Broadly Neutralizing Human Anti-HIV Monoclonal Antibody (10E8) Capable of Neutralizing Most HIV-1 Strains Only written comments and/or applications for a license which are received by the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, on or before July 27, 2020 will be considered.
View Prospective Grant of an Exclusive Patent License: Development and Commercialization of Fenoterol and Certain Fenoterol Analogues for the Treatment of Cancer Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before July 7, 2020 will be considered.
View Prospective Grant of an Exclusive Patent License: Ointment for the Topical Administration to Ischemic Treat and/or Neuropathic Ulcers in Humans Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before July 7, 2020 will be considered.
View Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before July 6, 2020 will be considered.
View Listing of Patent Information in the Orange Book; Establishment of a Public Docket; Request for Comments Submit either electronic or written comments by August 31, 2020.
View Prospective Grant of an Exclusive Patent License: Antibody-Based Therapy for the Treatment of CD20 Expressing Lymphomas Only written comments and/or applications for a license which are received by the National Heart, Lung, and Blood on or before June 8, 2020 will be considered.